Harry Dolstra, Professor of Translational Immunohematology, Head Cell Therapy Facility at Radboudumc, shared a post on LinkedIn:
“Exciting Milestone in NK Cell Therapy
We are happy to share that results from our Phase I clinical study (NCT03539406) with RNK001 stem cell-derived NK cells have been published in Gynecologic Oncology!
Key Highlights
- Safety & Feasibility: Intraperitoneal infusion of RNK001 with IL-2 support was safe and well tolerated in recurrent ovarian cancer patients, with no severe toxicity observed.
- Clinical Activity: 4 out of 6 patients showed a transient reduction in CA125 serum levels (20–53%) following RNK001 infusion – notably achieved without Cy/Flu lymphodepletion.
- Future Direction: Findings support further development of repeated NK cell infusion protocols to enhance therapeutic benefit.
This milestone reflects our commitment to advancing next-generation NK cell therapies through rigorous research, clinical translation, and innovation. A heartfelt thank you to our investigators, team members and the KWF Kankerbestrijding for their financial support (Grant number 10100).
Stay tuned for more updates on the development of off-the-shelf engineered stem cell-derived RNK products!
Interested in partnering.
More posts about NK Cell Therapy on OncoDaily.